759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

• Lawrence Fong,
• Sumit Subudhi,
• Gerald S Falchook,
• Russell Pachynski,
• Anthony El-Khoueiry,
• Ian Walters,
• Robert Krämer,
• Sushant Kumar,
• Kasim Mookhtiar,
• Justin Fairchild,
• Mohamad A Salkeni,
• Jaspreet Grewal,
• William Tester,
• Samik Upadhaya,
• Ana Rosa Saez Ibanez,
• Desa Rae Stanton-Pastore

Affiliations

Lawrence Fong

11University of California San Francisco, San Francisco, CA, USA

Sumit Subudhi

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Gerald S Falchook

2Sarah Cannon Research Institute, Denver, CO, USA

Russell Pachynski

7Washington University School of Medicine, St Louis, MO, USA

Anthony El-Khoueiry

4USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Ian Walters

10Tarus Therapeutics (a Portage Biotech company), Westport, CT, USA

Robert Krämer

10Tarus Therapeutics (a Portage Biotech company), Westport, CT, USA

Sushant Kumar

9Tarus Therapeutics, North Bergen, NJ, USA

Kasim Mookhtiar

10Tarus Therapeutics (a Portage Biotech company), Westport, CT, USA

Justin Fairchild

10Tarus Therapeutics (a Portage Biotech company), Westport, CT, USA

Mohamad A Salkeni

3Virginia Cancer Specialists, Fairfax, VA, USA

Jaspreet Grewal

5Norton Cancer Institute, Louisville, KY, USA

William Tester

6Thomas Jefferson University, Philadelphia, PA, USA

Samik Upadhaya

8Cancer Research Institute, New York, NY, USA

Ana Rosa Saez Ibanez

8Cancer Research Institute, New York, NY, USA

Desa Rae Stanton-Pastore

10Tarus Therapeutics (a Portage Biotech company), Westport, CT, USA